High Free Cash Flow Stocks
BIIB is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
BIOGEN INC (BIIB) Stock Price & Overview
NASDAQ:BIIB • US09062X1037
Current stock price
177.34 USD
-6.44 (-3.5%)
At close:
177.34 USD
0 (0%)
After Hours:
The current stock price of BIIB is 177.34 USD. Today BIIB is down by -3.5%. In the past month the price decreased by -5.71%. In the past year, price increased by 44.2%.
BIIB Key Statistics
52-Week Range110.04 - 202.41
Current BIIB stock price positioned within its 52-week range.
1-Month Range171.365 - 192.99
Current BIIB stock price positioned within its 1-month range.
- Market Cap
- 26.026B
- P/E
- 11.60
- Fwd P/E
- 11.03
- EPS (TTM)
- 15.29
- Dividend Yield
- N/A
BIIB Stock Performance
Today
-3.5%
1 Week
-7.18%
1 Month
-5.71%
3 Months
-0.27%
Longer-term
6 Months +10.92%
1 Year +44.20%
2 Years -17.45%
3 Years -41.71%
5 Years -33.66%
10 Years -29.99%
BIIB Stock Chart
BIIB Stock Screens
BIIB currently appears in the following ChartMill screener lists.
Low P/E Stocks
BIIB is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
BIIB is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
BIIB Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BIIB. When comparing the yearly performance of all stocks, BIIB is one of the better performing stocks in the market, outperforming 77.01% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
BIIB Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to BIIB. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BIIB Earnings
On February 6, 2026 BIIB reported an EPS of 1.99 and a revenue of 2.28B. The company beat EPS expectations (20.87% surprise) and beat revenue expectations (1.26% surprise).
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 6, 2026
PeriodQ4 / 2025
EPS Reported$1.99
Revenue Reported2.279B
EPS Surprise 20.87%
Revenue Surprise 1.26%
BIIB Forecast & Estimates
43 analysts have analysed BIIB and the average price target is 210.62 USD. This implies a price increase of 18.77% is expected in the next year compared to the current price of 177.34.
For the next year, analysts expect an EPS growth of 5.16% and a revenue growth -3.94% for BIIB
Analysts
Analysts73.02
Price Target210.62 (18.77%)
EPS Next Y5.16%
Revenue Next Year-3.94%
BIIB Groups
Sector & Classification
BIIB Financial Highlights
Over the last trailing twelve months BIIB reported a non-GAAP Earnings per Share(EPS) of 15.29. The EPS decreased by -7.16% compared to the year before.
Income Statements
Revenue(TTM)9.89B
Net Income(TTM)1.29B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.07% | ||
| ROA | 4.39% | ||
| ROE | 7.08% | ||
| Debt/Equity | 0.34 |
Chartmill High Growth Momentum
EPS Q2Q%-42.15%
Sales Q2Q%-7.14%
EPS 1Y (TTM)-7.16%
Revenue 1Y (TTM)2.22%
BIIB Ownership
Ownership
Inst Owners97.35%
Shares146.76M
Float146.32M
Ins Owners0.16%
Short Float %2.96%
Short Ratio3.62
BIIB Latest News, Press Relases and Analysis
BIIB Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BIIB
Company Profile
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Company Info
IPO: 1991-09-17
BIOGEN INC
225 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Michel Vounatsos
Employees: 7500
Phone: 13023513367
BIOGEN INC / BIIB FAQ
Can you describe the business of BIOGEN INC?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
What is the stock price of BIOGEN INC today?
The current stock price of BIIB is 177.34 USD. The price decreased by -3.5% in the last trading session.
What is the dividend status of BIOGEN INC?
BIIB does not pay a dividend.
What is the ChartMill technical and fundamental rating of BIIB stock?
BIIB has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
How is the valuation of BIOGEN INC (BIIB) based on its PE ratio?
The PE ratio for BIOGEN INC (BIIB) is 11.6. This is based on the reported non-GAAP earnings per share of 15.29 and the current share price of 177.34 USD.
Can you provide the growth outlook for BIOGEN INC?
The Revenue of BIOGEN INC (BIIB) is expected to decline by -3.94% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of BIIB stock?
BIOGEN INC (BIIB) has a market capitalization of 26.03B USD. This makes BIIB a Large Cap stock.